China's HiFiBiO Therapeutics bags $75m Series D led by Mirae Asset Financial Group

China's HiFiBiO Therapeutics bags $75m Series D led by Mirae Asset Financial Group

Photo by Henk Vrieselaar on Unsplash

HiFiBiO Therapeutics, a clinical-stage biotherapeutics company, announced on Monday that it has raised $75 million in an oversubscribed Series D round funding led by new investor Mirae Asset Financial Group. The lead investor is a Korean global financial services group with $563 billion in assets under management.

Other new investors who participated in the round include B Capital Group, and a slew of Greater China-based investment firms including Sherpa Healthcare Partners, Maison Capital, Trinity Innovation Fund, Grand Mount, and Hong Kong’s HSTP Venture Fund.  

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter